Type 2 Diabetes

The rapid-acting insulin will now be used in infusion pumps to treat adults with Type 1 or Type 2 diabetes.

AstraZeneca announced approval of the SGLT2 inhibitor for the reduction of hospitalization for heart failure in type 2 diabetes patients in a release on Monday.

Katherine Talcott, MD, of the Cole Eye Institute, discusses the results of a study she co-authored from AAO 2019 that examined visual acuity outcomes after cataract extraction with IOL implantation with diabetic eyes.

Researchers writing in the New England Journal of Medicine report that a combination treatment of ticagrelor and aspirin leads to improved cardiovascular disease outcomes in patients with stable coronary artery disease and diabetes mellitus.

A presentation at AAO 2019 highlighted the ability of the EyeArt screening system to detect diabetic retinopathy with 95.5% sensitivity.

A study presented at AAO 2019 revealed that obstructive sleep apnea could be a risk factor for diabetic macular edema and refractory diabetic macular edema.

Rishi Singh, MD, staff physician at Cole Eye Institute, discusses the most common myths he sees surrounding diabetic macular edema and its treatment.

Hepatitis C virus infections are strongly linked to type 2 diabetes, according to new research.

The type 2 diabetes drug dapagliflozin reduces the risk for worsening heart failure or death from cardiovascular disease among individuals with heart failure and reduced ejection fraction, whether or not they have diabetes, shows a study published in the New England Journal of Medicine.

Adults with early type two diabetes and elevated cardiovascular risk may be able to safely take linagliptin or sulfonylurea (glimepiride) without increasing their risk of cardiovascular events, researchers report in JAMA.

A recent study of primary practices in England found Asian patients were 15% less likely to be prescribed insulin, while black patients were half as likely to be prescribed a GLP-1 agonist or SGLT2 inhibitor.

George Bakris, MD, professor of medicine at University of Chicago Medicine and member of CREDENCE steering committee, discusses the recent approval of canagliflozin and what it means for diabetic patients and their physicians.

African Americans are more greatly burdened by the cardiovascular condition and its common comorbidities. Are new therapies able to help?

A new study from the Harvard T.H. Chan School of Public Health found increasing consumption of sugary beverages, including 100% fruit juices, by half a serving per day could increase a person's risk of diabetes by 16%.

A recent study from the ACC Middle East Conference 2019 found patients with hypertension and type 2 diabetes who consume a high fiber diet had improvement in their blood pressure, cholesterol and fasting glucose.

A recent study of pregnancies from the Quebec Pregnancy Cohort found use of antidepressants during pregnancy was linked to an increased rate of gestational diabetes mellitus in an analysis that included more than 200,000 women from 1998 to 2015.

Among adults with recently-diagnosed type 2 diabetes and elevated cardiovascular risk, the dipeptidyl peptidase-4 (DPP-4) inhibitor linagliptin and the sulfonylurea glimepiride treatment resulted in similar cardiovascular outcomes over a median 6.3 years.

The diabetes management and adult health specialist reacts to the SGLT2 inhibitor's newest indication.

The SGLT2 inhibitor from Janssen has shown significant benefit for reducing progression to end-stage kidney disease, as well as risk for major adverse cardiovascular events.

Vanita Aroda, MD, of Brigham and Women's Hospital, discusses the impact of PIONEER trials and the implications the approval for oral semaglutide has on diabetes care.

A recent study into insulin use in adults 75 and older found insulin use was increased in those with worse health, indicating a lack of adherence to current guideline recommendations.

A new study shows that approximately one-quarter of adults aged 18-34 years old with a medical condition have used marijuna in the past month.

The therapy becomes the first oral GLP-1 agonist approved for the treatment of A1C reduction.

A recent study examining use of popular glucose-lowering medications found that metformin use was associated with fewer cardiovascular events in diabetic patients with reduced kidney function.

A new meta-analysis presented at EASD 2019 found that women who gave birth following use of assisted reproductive techniques had a 53% increased risk of gestational diabetes compared to women who conceived naturally.